• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AC Immune, Piramal Imaging ink agreement for Alzheimer's disease

AC Immune, Piramal Imaging ink agreement for Alzheimer's disease

May 15, 2014
CenterWatch Staff

AC Immune, a Swiss-based biopharmaceutical company, and Piramal Imaging, a division of Piramal Enterprises, have entered into an exclusive worldwide license agreement for the research, development and commercialization of AC Immune's Tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of Alzheimer's disease and potential Tau-related disorders.

The formation of Tau tangles in the human brain is recognized as one of two major hallmarks of Alzheimer's disease pathology, with the other being beta-amyloid plaques. The development of the Tau tangle pathology appears to correlate well with cognitive decline, making it a potential strong target for diagnostic approaches. The availability of a Tau-PET tracer for imaging Tau tangles in the brain of patients would represent important progress towards relevant diagnostic endpoints and could be of significant value in guiding clinical trials for disease modifying AD therapeutics.

AC Immune will work in collaboration with Piramal Imaging to efficiently advance several lead candidates through late preclinical radio-pharmacology development. Piramal Imaging will have global rights for clinical development, manufacturing and commercialization of a Tau-PET Tracer resulting from the collaboration. Financial details have not been disclosed.

Dr. Ludger Dinkelborg, director of the board of Piramal Imaging, said, "This collaboration with AC Immune is an important next step in our mission to developing molecular imaging innovations that allow an earlier and more accurate diagnosis of Alzheimer's disease. So far there are no approved imaging technologies to detect Tau protein in patients, presenting a challenge in AD diagnosis and the development of disease modifying treatments.”

The agreement between the two companies is based on a long-term relationship in which AC Immune has used Piramal Imaging's beta-amyloid PET Tracer Neuraceq for imaging beta-amyloid plaques in the brain of patients undergoing phase I/IIa clinical testing of AC Immune´s Alzheimer´s vaccine ACI-24.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing